Bonesupport Holding Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 4/6
Bonesupport Holding verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 53.5%, während die Gewinne der Branche Biotechs jährlich um gewachsen und zwar um 30%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 38.5%. Die Eigenkapitalrendite von Bonesupport Holding beträgt 19.7% und die Nettomargen betragen 15.2%.
Wichtige Informationen
53.46%
Wachstumsrate der Gewinne
53.50%
EPS-Wachstumsrate
| Biotechs Wachstum der Industrie | 0.71% |
| Wachstumsrate der Einnahmen | 38.49% |
| Eigenkapitalrendite | 19.72% |
| Netto-Marge | 15.23% |
| Nächste Ertragsaktualisierung | 16 Jul 2026 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
Apr 25
BONEX: Clinical Pilot Infection Outcomes Will Support Future Upside Potential
Analysts have raised their price target for Bonesupport Holding by about SEK 10.60 to SEK 377.17, citing updated assumptions that include a slightly higher discount rate, adjusted revenue growth expectations, a revised profit margin outlook, and a lower future P/E multiple. What's in the News Bonesupport Holding announced the first publication of a US clinical pilot study on the surgical technique and outcomes of CERAMENT G in trauma.BONEX: Clinical Pilot Outcomes And 2026 Sales Outlook Will Support Future Upside Potential
Analysts have revised their price target on Bonesupport Holding to SEK 366.6. The update reflects an unchanged fair value along with adjusted assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News Publication of a US clinical pilot study in OTA International highlighting surgical technique and outcomes for CERAMENT G in trauma cases, providing practical, real world guidance for clinicians considering the product in fracture related infections and osteomyelitis (Key Developments).BONEX: Clinical Pilot Outcomes And 2025 Guidance Will Support Future Upside Potential
Analysts have kept their SEK price target for Bonesupport Holding unchanged at SEK 366.60, citing broadly consistent assumptions on discount rate, revenue growth, profit margin and future P/E. Together, these factors support a steady valuation view.
Slow Trauma Center Adoption And Regulatory Hurdles Will Eventually Support A Healthier Business Mix
Catalysts About Bonesupport Holding Bonesupport Holding develops and sells CERAMENT bone void fillers, including antibiotic eluting products used to treat complex bone infections and defects. What are the underlying business or industry changes driving this perspective?BONEX: Clinical Pilot Results And Strong Guidance Will Support Long-Term Upside Potential
Analysts have trimmed their price target on Bonesupport Holding by SEK 4 to SEK 366.6. This reflects updated assumptions around discount rates, revenue growth and profitability, while keeping future P/E expectations broadly in line with previous views. What's in the News Bonesupport announced the first publication of a US clinical pilot study on the surgical technique and outcomes of CERAMENT G in trauma, giving clinicians practical, real world insights into its use in trauma cases.
US Trauma Expansion And New Surgical Uses Will Transform This Bone Regeneration Specialist
Catalysts About Bonesupport Holding Bonesupport Holding develops and sells CERAMENT bone void fillers, including antibiotic eluting products such as CERAMENT G and CERAMENT V, for use in complex bone infections and orthopedic procedures. What are the underlying business or industry changes driving this perspective?BONEX: De Novo Shift Will Support Long Term Upside Potential
Analysts have slightly trimmed their fair value estimate for Bonesupport Holding to SEK370.6, from SEK374.6, reflecting minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions, while keeping the overall thesis broadly intact. What's in the News Bonesupport issued earnings guidance for Q4 2025, with net sales expected at 313 MSEK at constant exchange rates, based on company guidance for that period (company guidance).Is There An Opportunity With Bonesupport Holding AB (publ)'s (STO:BONEX) 43% Undervaluation?
Feb 12BONEX: De Novo Pathway Shift Will Support Long Term Upside Potential
Analysts have kept their fair value estimate for Bonesupport Holding steady at SEK374.60 per share. The latest price target update mainly reflects small technical tweaks to the discount rate and future P/E assumptions rather than a shift in the core outlook.BONEX: De Novo Review Shift Will Support Long Term Upside Potential
Analysts have trimmed their price target for Bonesupport Holding to SEK 374.60 from SEK 391.20, citing slightly lower assumptions for revenue growth and profit margins, along with a higher future P/E multiple. What's in the News Bonesupport Holding issued earnings guidance for the fourth quarter of 2025 with net sales expected at SEK 313 M, based on constant exchange rates (Corporate guidance).BONEX: De Novo Pathway Shift Will Support Long Term Upside Potential
Analysts have kept their fair value estimate for Bonesupport Holding steady at SEK391.20, with only minor tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. This suggests their overall view on the company’s long term potential is essentially unchanged.BONEX: De Novo Pathway Shift Will Support Strong Future Market Position
Analysts have modestly raised their price target on Bonesupport Holding, citing a slightly lower discount rate and improved visibility into sustaining approximately 38 percent revenue growth and robust 31 percent profit margins. Together, these factors support a fair value of SEK 391.20 per share.BONEX: Hip Infection Study Success Will Drive Stronger Future Clinical And Market Position
Analysts have modestly raised their price target on Bonesupport Holding to SEK 391.2 per share from SEK 391.2 per share, reflecting largely unchanged long term assumptions on the discount rate, revenue growth, profit margins and future valuation multiples. What's in the News Positive top line data from the CeraHip clinical study show that CERAMENT G enabled successful single stage revision surgery for periprosthetic joint infection of the hip, with no re infections reported over 24 months of follow up (Key Developments).BONEX: Positive Study Results Will Support Improvements In Hip Infection Outcomes
Analysts have adjusted their price target for Bonesupport Holding, maintaining it at SEK 391.20. Recent evaluations indicate steady expectations in light of updated discount rates and continued confidence in the company's growth and profitability outlook.Bonesupport Holding AB (publ) (STO:BONEX) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
Nov 22BONEX: Clinical Study Results Will Drive Long-Term Patient Outcome Improvements
Bonesupport Holding's analyst price target has been updated downward from SEK 401.80 to SEK 391.20, as analysts factor in slightly softer revenue growth forecasts and a higher discount rate. What's in the News Bonesupport announced positive results from a clinical study showing significantly improved patient-reported outcomes for CERAMENT G in single-stage revision surgery for periprosthetic joint infection of the hip (Key Developments).Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
Oct 28Positive Clinical Results And US Launch Will Drive Future Success
Analysts have revised their price target for Bonesupport Holding from SEK 419.75 to SEK 401.80. This change reflects adjustments to growth and profitability assumptions.Bonesupport Holding AB (publ)'s (STO:BONEX) Shares May Have Run Too Fast Too Soon
Aug 25Bonesupport Holding's (STO:BONEX) Soft Earnings Are Actually Better Than They Appear
Jul 23Bonesupport Holding AB (publ)'s (STO:BONEX) Intrinsic Value Is Potentially 80% Above Its Share Price
Jun 28Analyst Estimates: Here's What Brokers Think Of Bonesupport Holding AB (publ) (STO:BONEX) After Its First-Quarter Report
Apr 28
CERAMENT G's US Launch And CERAMENT V's FDA Submission Will Expand Global Presence
CERAMENT G's rapid U.S. penetration addresses a significant market need, likely causing notable revenue growth due to its strong clinical backing.kr445 - That's What Analysts Think Bonesupport Holding AB (publ) (STO:BONEX) Is Worth After These Results
Mar 01Earnings Troubles May Signal Larger Issues for Bonesupport Holding (STO:BONEX) Shareholders
Oct 31Aufschlüsselung der Einnahmen und Ausgaben
Wie Bonesupport Holding Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Gewinn | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 Mar 26 | 1,215 | 185 | 741 | 93 |
| 31 Dec 25 | 1,175 | 142 | 719 | 91 |
| 30 Sep 25 | 1,119 | 152 | 705 | 90 |
| 30 Jun 25 | 1,062 | 148 | 677 | 89 |
| 31 Mar 25 | 998 | 122 | 657 | 86 |
| 31 Dec 24 | 899 | 134 | 609 | 76 |
| 30 Sep 24 | 814 | 91 | 575 | 72 |
| 30 Jun 24 | 735 | 289 | 539 | 65 |
| 31 Mar 24 | 656 | 267 | 498 | 59 |
| 31 Dec 23 | 591 | 245 | 462 | 57 |
| 30 Sep 23 | 522 | 214 | 420 | 54 |
| 30 Jun 23 | 448 | -30 | 383 | 54 |
| 31 Mar 23 | 382 | -51 | 342 | 53 |
| 31 Dec 22 | 329 | -68 | 312 | 53 |
| 30 Sep 22 | 287 | -72 | 279 | 53 |
| 30 Jun 22 | 257 | -71 | 249 | 51 |
| 31 Mar 22 | 234 | -82 | 236 | 53 |
| 31 Dec 21 | 213 | -86 | 221 | 53 |
| 30 Sep 21 | 205 | -88 | 212 | 55 |
| 30 Jun 21 | 198 | -96 | 214 | 55 |
| 31 Mar 21 | 182 | -92 | 197 | 54 |
| 31 Dec 20 | 181 | -101 | 201 | 58 |
| 30 Sep 20 | 174 | -115 | 207 | 60 |
| 30 Jun 20 | 165 | -127 | 204 | 66 |
| 31 Mar 20 | 166 | -151 | 227 | 68 |
| 31 Dec 19 | 155 | -161 | 226 | 69 |
| 30 Sep 19 | 132 | -166 | 213 | 68 |
| 30 Jun 19 | 108 | -191 | 215 | 67 |
| 31 Mar 19 | 98 | -182 | 199 | 68 |
| 31 Dec 18 | 97 | -176 | 192 | 66 |
| 30 Sep 18 | 101 | -182 | 181 | 68 |
| 30 Jun 18 | 119 | -146 | 163 | 65 |
| 31 Mar 18 | 128 | -132 | 148 | 66 |
| 31 Dec 17 | 129 | -129 | 150 | 61 |
| 30 Sep 17 | 132 | -112 | 153 | 56 |
| 30 Jun 17 | 126 | -124 | 154 | 54 |
| 31 Mar 17 | 114 | -124 | 160 | 42 |
| 31 Dec 16 | 105 | -110 | 140 | 38 |
| 31 Dec 15 | 62 | -60 | 88 | 19 |
Qualität der Erträge: BONEX hat hohe Qualitätseinkünfte.
Wachsende Gewinnspanne: BONEXDie aktuellen Gewinnspannen (15.2%) sind höher als im letzten Jahr (12.3%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: BONEX ist in den letzten 5 Jahren profitabel geworden und hat seinen Gewinn um 53.5% pro Jahr gesteigert.
Beschleunigtes Wachstum: BONEXDas Gewinnwachstum des Unternehmens im letzten Jahr (51.3%) liegt unter seinem 5-Jahres-Durchschnitt (53.5% pro Jahr).
Erträge im Vergleich zur Industrie: BONEX Das Gewinnwachstum im vergangenen Jahr (51.3%) übertraf das der Branche Biotechs 45% .
Eigenkapitalrendite
Hohe Eigenkapitalrendite: BONEXDie Eigenkapitalrendite des Unternehmens (19.7%) wird als niedrig angesehen.
Kapitalrendite
Rendite auf das eingesetzte Kapital
Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/04/29 16:08 |
| Aktienkurs zum Tagesende | 2026/04/29 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Bonesupport Holding AB (publ) wird von 8 Analysten beobachtet. 6 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| null null | ABG Sundal Collier |
| Erik Cassel | Danske Bank |
| Kristofer Liljeberg-Svensson | DNB Carnegie |